CADL
NASDAQCandel Therapeutics Inc.
Price$8.19-0.66 (-7.51%)
01:30 PM07:15 PM
News · 26 weeks62+13%
2026-04-192026-10-11
Mix2490d
- Other10(42%)
- Insider7(29%)
- SEC Filings4(17%)
- Leadership2(8%)
- Analyst1(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Loggia Nicoletta4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- INSIDERSEC Form 4 filed by Director Papa Joseph C4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- INSIDERSEC Form 4 filed by Director Manning Paul B4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- PRCandel Therapeutics to Present at the SITC 2026 Annual MeetingNEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present data from its aglatimagene besadenovec program in non-small cell lung cancer (NSCLC) in patients with progressive NSCLC despite immune checkpoint inhibitor (ICI) treatment, as well as clinical and mechanistic findings from its phase 1b clinical trial of linoserpaturev in recurrent glioblastoma, through two accepted poster presentations at the Society for Immunotherapy of Cancer's (SITC) 4
- PRCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on September 30, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to 4 new employees, stock options to purchase an aggregate of 85,900 shares of the Company’s common stock, with a per share exercise price of $10.44. The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest with respect to 25% of the shares of common stock underlyin
- PRCandel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICIPeer-reviewed publication in Journal for ImmunoTherapy of Cancer reports median overall survival of 24.5 months in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint inhibitors (ICI) NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the publication of final phase 2a clinical trial results (NCT04495153) of aglatimagene besadenovec (aglatimagene) plus valacyclovir in patients with stage III/IV NSCLC who had shown inadequ
- PRCandel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate CancerNovel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with recently disclosed evidence of persistent local immune remodeling, these findings provide mechanistic support for the long-term clinical outcomes, including disease-free survival and prolonged time to biochemical failure, time to metastasis, and time to salvage anti-cancer therapy, observed in this patient populationBiodistribution and shedding data from the PrTK05 phase 2 trial remain on track for inclusion in the planned Q4 2026 Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for localized prostate cancer NEEDHAM, Mass., Sep
- PRCandel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026AI-enabled digital pathology analysis shows aglatimagene significantly increased lymphocyte infiltration and immune engagement with tumor cells compared to standard-of-care radiotherapy alone two years after treatment NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the presentation of new biomarker data from its completed phase 3 clinical trial of aglatimagene besadenovec (aglatimagene) in patients with localized intermediate- to high-risk prostate cancer at the
- ANALYSTCandel Therapeutics upgraded by BofA Securities with a new price targetBofA Securities upgraded Candel Therapeutics from Neutral to Buy and set a new price target of $18.00
- INSIDERChief Executive Officer Tak Paul Peter exercised 125,000 shares at a strike of $1.55 and sold $3,160,783 worth of shares (280,245 units at $11.28) as part of a pre-agreed trading plan, decreasing direct ownership by 58% to 113,321 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- INSIDERSEC Form 4 filed by Director Zimmermann Martine4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- INSIDERSEC Form 3 filed by new insider Zimmermann Martine3 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SECCandel Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Candel Therapeutics, Inc. (0001841387) (Filer)
- PRCandel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of DirectorsRegulatory and quality expertise strengthens Board as Candel advances toward planned Biologics License Application (BLA) submission and potential commercial readiness NEEDHAM, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Martine Zimmermann, PharmD, to the Company’s Board of Directors (Board) effective September 8, 2026. "Martine joins Candel at an important stage in our evolution, as we prepare for the planned submission of the BLA for aglatimagene
- SECCandel Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Candel Therapeutics, Inc. (0001841387) (Filer)
- PRCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEEDHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on August 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to two new employees, stock options to purchase an aggregate of 31,400 shares of the Company’s common stock, with a per share exercise price of $13.07. The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest with respect to 25% of the shares of common stock underlyin
- PRCandel Therapeutics to Present at September Investor ConferencesNEEDHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in analyst-led fireside discussions and one-on-one meetings at upcoming investor conferences in September 2026. Key Details: Citi's 2026 Biopharma Back to School Conference (New York, NY)Date/Time: Wednesday, September 9, 2026, at 10:00AM ETWebcast Link: Citi / Candel Fireside Chat 2026 Cantor Global Healthc
- INSIDERChief Technology Officer Tyagarajan Seshu sold $84,000 worth of shares (7,000 units at $12.00) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 76,865 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SECSEC Form 10-Q filed by Candel Therapeutics Inc.10-Q - Candel Therapeutics, Inc. (0001841387) (Filer)
- SECCandel Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Candel Therapeutics, Inc. (0001841387) (Filer)
- PRCandel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate HighlightsPlanning to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene) in localized, intermediate- to high-risk prostate cancer in Q4 2026Pivotal phase 3 clinical data published in The Lancet Oncology demonstrated a statistically significant improvement in disease-free survival with aglatimagene plus standard-of-care radiotherapy compared with radiotherapy alone in patients with localized, intermediate- to high-risk prostate cancerPresented supportive clinical data from extended follow-up of the phase 3 clinical trial of aglatimagene in patients with localized, intermediate- to high-risk prostate cancer in a plenary oral presentation at the American Urological A
- PRCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on July 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to three new employees, stock options to purchase an aggregate of 30,800 shares of the Company’s common stock, with a per share exercise price of $10.01. The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest with respect to 25% of the shares of common stock underlying
- PRCandel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that an abstract was accepted for poster presentation at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place September 26-30, 2026, in Boston, MA. Aglatimagene besadenovec – Localized Prostate Cancer Abstract Title: Quantitative Digital Pathology Defines Immune Activation Following Aglatimagene Besadenovec Immunotherapy in Localized Prostate CancerPresenter: Francesca Barone, M
- PRCandel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in BostonNEEDHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present at Canaccord Genuity’s 46th Annual Growth Conference, taking place August 11-13, 2026, in Boston, MA. Presentation Details: Date: Wednesday, August 12, 2026Time: 12 PM EDTWebcast Link: Canaccord Genuity / Candel Presentation A webcast of the presentation will be available by selecting Events and Presentations in the Investors section of Candel’s website at www.candeltx.com. A replay of
- ANALYSTStifel initiated coverage on Candel Therapeutics with a new price targetStifel initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $22.00
CADL FAQ
7 questionsWhat does Candel Therapeutics Inc. do?
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of cancer immunotherapy drugs. The company offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. Its product candidates include CAN-2409, an off-the-shelf adenovirus product candidate, for the treatment of localized, primary prostate cancer and therapy for pancreatic cancer; and CAN-3110, its HSV product candidate...Where does CADL stock trade?
Candel Therapeutics Inc. (CADL) is listed on NASDAQ.What sector and industry is CADL in?
Candel Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Candel Therapeutics Inc. go public?
Candel Therapeutics Inc. (CADL) completed its IPO in 2021.What are analysts saying about CADL?
Candel Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Buy with a $1800.00 price target on 2026-09-21. Recent price targets range from $700.00 to $2500.00.What companies are similar to CADL?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare CADL side-by-side with any of them on Quantisnow.How can I track CADL on Quantisnow?
Quantisnow aggregates Candel Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CADL to receive live email and push alerts on every new disclosure.